GlassScriptPhysician profile
Anthony J Badame
NPI 1285676551
$2,473.04
in general payments reported to CMS, 2019-2025
20 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $196 · 2021: $80.00 · 2022: $181 · 2023: $942 · 2024: $525 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.84 |
| Education | $215.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $526.50 | 2020-2025 | Dupixent |
| Abbvie INC. | $378.46 | 2023-2024 | Skyrizi, Rinvoq |
| Ucb, INC. | $249.47 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $215.87 | 2022-2024 | Aklief, Epsolay |
| Janssen Scientific Affairs, LLC | $196.00 | 2019-2020 | |
| Dermira, INC. | $125.00 | 2019 | |
| Genzyme Corporation | $124.70 | 2023 | |
| Sun Pharmaceutical Industries INC. | $119.47 | 2023-2024 | Absorica Ld, Winlevi |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Lilly USA, LLC | $88.36 | 2019 | |
| Janssen Biotech, INC. | $70.04 | 2023 | Tremfya |
| Pfizer INC. | $64.23 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $43.80 | 2023 | |
| Smith+Nephew, INC. | $36.26 | 2023 | Grafix |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.42 | 2023 | Jublia, Duobrii, Arazlo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $30.27 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $23.10 | 2022 | |
| Dermavant Sciences, INC. | $17.81 | 2023 | Vtama |
| Novartis Pharmaceuticals Corporation | $16.04 | 2023 | |
| Verrica Pharmaceuticals INC. | $13.24 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Badame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.